全文获取类型
收费全文 | 386篇 |
免费 | 15篇 |
国内免费 | 1篇 |
专业分类
儿科学 | 1篇 |
基础医学 | 61篇 |
口腔科学 | 1篇 |
临床医学 | 26篇 |
内科学 | 150篇 |
特种医学 | 1篇 |
外科学 | 30篇 |
预防医学 | 2篇 |
药学 | 110篇 |
肿瘤学 | 20篇 |
出版年
2021年 | 5篇 |
2019年 | 10篇 |
2018年 | 6篇 |
2017年 | 4篇 |
2016年 | 2篇 |
2015年 | 4篇 |
2014年 | 10篇 |
2013年 | 14篇 |
2012年 | 16篇 |
2011年 | 17篇 |
2010年 | 13篇 |
2009年 | 11篇 |
2008年 | 18篇 |
2007年 | 21篇 |
2006年 | 17篇 |
2005年 | 13篇 |
2004年 | 9篇 |
2003年 | 5篇 |
2002年 | 5篇 |
2001年 | 2篇 |
2000年 | 8篇 |
1999年 | 10篇 |
1998年 | 4篇 |
1996年 | 2篇 |
1995年 | 2篇 |
1994年 | 3篇 |
1993年 | 2篇 |
1992年 | 7篇 |
1991年 | 17篇 |
1990年 | 9篇 |
1989年 | 16篇 |
1988年 | 17篇 |
1987年 | 9篇 |
1986年 | 11篇 |
1985年 | 10篇 |
1984年 | 11篇 |
1983年 | 7篇 |
1981年 | 2篇 |
1980年 | 5篇 |
1979年 | 7篇 |
1977年 | 5篇 |
1974年 | 3篇 |
1973年 | 3篇 |
1972年 | 4篇 |
1971年 | 3篇 |
1970年 | 2篇 |
1969年 | 4篇 |
1968年 | 2篇 |
1966年 | 3篇 |
1965年 | 2篇 |
排序方式: 共有402条查询结果,搜索用时 19 毫秒
1.
Nishida Koyo Mihara Kiyoshi Takino Toichi Nakane Sachi Takakura Yoshinobu Hashida Mitsuru Sezaki Hitoshi 《Pharmaceutical research》1991,8(4):437-444
The effect of electric charge on the hepatic disposition of macromolecules was studied in the rat. Charged derivatives of dextran (T-70) and bovine serum albumin (BSA), mitomycin C–dextran conjugates (MMC-D), and lactosaminated BSA (Lac-BSA) were employed as model macromolecules. After intravenous injection, cationic macromolecules were rapidly eliminated from plasma because of their extensive hepatic uptake, while anionic and neutral macromolecules were slowly eliminated. Cationic macromolecules were recovered from parenchymal and nonparenchymal hepatic cells at a cellular uptake (per unit cell number) ratio of 1.4–3.2, while that of Lac-BSA was 14. During liver perfusion using a single-pass constant infusion mode, cationic macromolecules were continuously extracted by the liver, with extraction ratios at steady-state (E
ss) ranging between 0.03 and 0.54, whereas anionic and neutral macromolecules were almost completely recovered in the outflow at steady state. The E
ss for cationized BSA (Cat-BSA) and cationic MMC-Dcat were concentration dependent and decreased at low temperatures and in the presence of colchicine and cytochalasin B. The possible participation of the internalization process in the uptake of cationic macromolecules by hepatocytes was suggested. 相似文献
2.
Takakura Yoshinobu Fujita Takuya Hashida Mitsuru Sezaki Hitoshi 《Pharmaceutical research》1990,7(4):339-346
As part of the strategy for the design of macromolecular carriers for drug targeting, the disposition characteristics of macromolecules were studied in mice bearing tumors that served as target tissues. Eight kinds of macromolecules including four polysaccharides and four proteins with different molecular weights and electric charges were used; tissue distribution and tumor localization after intravenous injection were studied. Pharmacokinetic analysis revealed that the tissue radioactivity uptake rate index calculated in terms of clearance was different among the tested compounds; especially, the urinary radioactivity excretion clearances and the total hepatic radioactivity uptake clearances varied widely. Compounds with low molecular weights (approximately 10 kD) or positive charges showed lower tumor radioactivity accumulation; radioactivity was rapidly eliminated from the plasma via rapid urinary excretion or extensive hepatic uptake, respectively. On the other hand, large and negatively charged compounds, carboxymethyl dextran, bovine serum albumin, and mouse immunoglobulin G, showed higher radioactivity accumulation in the tumor (calculated total amounts were 15.6, 10.8, and 20.8% of the dose, respectively) and prolonged retention in the circulation. These results demonstrated that the total systemic exposure rather than the uptake rate index was correlated with total tumor uptake. Molecular weight and electric charge of the macromolecules significantly affected their disposition characteristics and, consequently, determined radioactivity accumulation in the tumor. It was concluded that a drug–carrier complex designed for systemic tumor targeting should be polyanionic in nature and larger than 70,000 in molecular weight. 相似文献
3.
M Hatsu T Sasaki S Gomi Y Kodama M Sezaki S Inouye S Kondo 《The Journal of antibiotics》1992,45(3):325-330
The structure of a new antitumor antibiotic SF2575, has been determined by spectroscopic analyses of the antibiotic and its alkaline degradation products. The relative stereochemistry has been confirmed by X-ray crystallographic analysis. The antibiotic has a 2-naphthacenecarboxamide carbon skelton which is structurally related to the tetracycline antibiotics and it is unique by bearing C-glycoside, salicyclic acid and angelic acid moieties. 相似文献
4.
Favorable efficacy of long-term lamivudine therapy in patients with chronic hepatitis B: an 8-year follow-up study 总被引:7,自引:0,他引:7
Akuta N Suzuki F Suzuki Y Sezaki H Hosaka T Someya T Kobayashi M Saitoh S Arase Y Ikeda K Kobayashi M Kumada H 《Journal of medical virology》2005,75(4):491-498
The long-term efficacy of lamivudine therapy in patients with hepatitis B virus (HBV) infection is still not clear. In this study, 20 non-cirrhotic Japanese patients infected with HBV received lamivudine therapy for more than 1 year and were followed for a median period of 8.5 years (range, 6.7-8.7 years). The rates of HBe antigen (HbeAg) negative, HBV-DNA undetectable, and alanine aminotransferase (ALT) normal level at the start of lamivudine were 55%, 25%, and 20% and 85%, 80%, and were 80%, respectively, at the last visit, including patients who received additional treatment. The values at the last visit tended to and were significantly higher than those at the start. The values improved at the last visit regardless of the emergence of YMDD motif mutant and continuation of lamivudine. YMDD mutant and biochemical relapse with mutant virus (breakthrough hepatitis) appeared in 65% and 45% during follow-up, respectively, but severe breakthrough hepatitis occurred in only 5%. Furthermore, 80% of patients who received additional treatment for breakthrough hepatitis, regardless of continuation of lamivudine, were ALT normal level at the last visit, in contrast to 25% untreated. HBsAg clearance occurred in two patients of the discontinuous lamivudine group with non-vertical transmission, who were relatively young. One was infected with HBV genotype C with breakthrough hepatitis and the other had no YMDD mutant and was infected with genotype D, a rare type in Japan. None developed cirrhosis or hepatocellular carcinoma (HCC) during follow-up. Our results suggest that long-term lamivudine therapy improves long-term prognosis, especially when additional treatment for breakthrough hepatitis is used. 相似文献
5.
Kataoka M Masaoka Y Yamazaki Y Sakane T Sezaki H Yamashita S 《Pharmaceutical research》2003,20(10):1674-1680
Purpose. The aim of the present work was to develop a new in vitro system to evaluate oral absorption of poorly water-soluble drugs by utilizing Caco-2 monolayers.
Methods. Caco-2 monolayer was mounted between side-by-side chambers, which enabled the simultaneous assay of dissolution and permeation of drugs (dissolution/permeation system; D/P system). Apical and basal sides of the chamber were filled with buffer solutions. Drugs were applied to the apical side as powder, suspension, or solution, and then, the permeated amounts into the basal side were monitored for 2 h. At the same time, dissolved amounts of drugs at the apical side were detected. The amount of drug applied to the D/P system was based on its in vivo clinical dose.
Results. Sodium taurocholate (5 mM, apical side) and bovine serum albumin (4.5% w/v, basal side) increased the permeated amount of poorly water-soluble drugs. Both additives were considered to be effective at mimicking in vivo conditions of intestinal drug absorption. From the correlation between the permeated amount of 13 drugs (% dose/2 h) in the D/P system and their percentage dose absorbed in humans in vivo, this system was found to be useful in evaluating oral absorption of poorly water-soluble drugs.
Conclusions. With attempts made to mimic the physiologic conditions of the human GI tract, in vivo oral absorption of drugs was quantitatively assessed in the D/P system in vitro. This system is quite useful to predict the oral absorption of poorly water-soluble drugs after administration as solid dosage forms. 相似文献
6.
Eiko Hasegawa Masahiro Kobayashi Yusuke Kawamura Hiromi Yatsuji Hitomi Sezaki Tetsuya Hosaka Norio Akuta Fumitaka Suzuki Yoshiyuki Suzuki Yasuji Arase Kenji Ikeda Hiromitsu Kumada 《Hepatology research》2007,37(10):793-800
Background: We assessed the efficacy and anticarcinogenic effects of interferon (IFN) therapy in patients with hepatitis C virus (HCV)-related cirrhosis. Methods: The study subjects were 123 Japanese patients with HCV-related cirrhosis with genotype 1b low viral load or genotype 2 who received IFN from 1989 to 2005 (18 patients continue to receive IFN therapy). They included 81 men and 42 women aged 29-74 years (median, 56 years). Results: Univariate analysis identified four parameters that significantly influenced SVR; viral load (low HCV concentration, P < 0.001), duration of IFN therapy (>/= 52 weeks, P = 0.029), daily dose of IFN (>/= 6 million units, P = 0.018), induction therapy (presence, P = 0.010) and choline esterase (> 1.0 DeltapH, P = 0.037). Multivariate analysis identified viral load (risk ratio = 6.329, P < 0.001) and daily dose of IFN (risk ratio = 2.62, P = 0.042) as two independent parameters thatinfluenced SVR. During the observation period, newly developed hepatocellular carcinoma (HCC) was detected in 22 patients. The rates of development of HCC in patients with SVR were 5.8% at the fifth year and 10.3% at the 10th year, compared with 25.8% at the fifth year and 42.5% at the 10th year in non-SVR patients. Multivariate analysis showed that IFN efficacy (SVR) was the only independent factor of hepatocarcinogenesis (hazard ratio: 0.185, 95% confidence interval: 0.042-0.810, P = 0.025) Conclusion: Among patients with HCV-related cirrhosis, the rate of development of HCC is significantly less in patients with SVR. 相似文献
7.
Kayoko Kasuya Yusuke Kawamura Masahiro Kobayashi Junichi Shindoh Yuta Kobayashi Akira Kajiwara Soichi Iritani Shunichiro Fujiyama Tetsuya Hosaka Satoshi Saitoh Hitomi Sezaki Norio Akuta Fumitaka Suzuki Yoshiyuki Suzuki Kenji Ikeda Yasuji Arase Yuichiro Eguchi Masaji Hashimoto Hiromitsu Kumada 《Internal medicine (Tokyo, Japan)》2021,60(3):345
Objective A survival benefit was demonstrated for ramucirumab (RAM) in patients with unresectable hepatocellular carcinoma (uHCC) and α-fetoprotein (AFP) concentrations ≥400 ng/mL who had previously received sorafenib (SOR). However, it is unclear whether RAM has a similar efficacy in patients with uHCC that progresses after lenvatinib (LEN) treatment. This study aimed to evaluate the early anti-tumor response to RAM as a second-line treatment for advanced uHCC after LEN treatment. Methods We retrospectively assessed the efficacy and safety of RAM at 6 weeks after initiation. The therapeutic effects were evaluated according to the Response Evaluation Criteria in Solid Tumors version 1.1. Patients We evaluated 7 patients with uHCC who received RAM as a second- or third-line treatment after LEN failure. Results The disease control rate (DCR) was 28.6% (2 of 7 patients). After the initiation of RAM, a rapid disease progression resulted in 1 patient death after 19 days. The median progression-free survival (PFS) was 41 days. There were no grade 3 or 4 treatment-related adverse events. At 6 weeks, there was no deterioration in the modified albumin-bilirubin (mALBI) grade. In patients with an imaging response of stable disease (SD), the rate of AFP production decreased from the baseline. Conclusion RAM may have a therapeutic potential for the suppression of uHCC progression in patients previously treated with LEN, as well as for maintaining the liver function during treatment. Evaluating the AFP trends may therefore be useful for predicting RAM effectiveness. 相似文献
8.
Norio Akuta Fumitaka Suzuki Taito Fukushima Yusuke Kawamura Hitomi Sezaki Yoshiyuki Suzuki Tetsuya Hosaka Masahiro Kobayashi Tasuku Hara Mariko Kobayashi Satoshi Saitoh Yasuji Arase Kenji Ikeda Hiromitsu Kumada 《Journal of clinical microbiology》2013,51(9):2862-2868
It is often difficult to predict the response to telaprevir-pegylated interferon (PEG-IFN)-ribavirin triple therapy and the appearance of telaprevir-resistant variants. The present study determined the predictive factors of a sustained virological response (SVR) to 12- or 24-week triple therapy (T12PR12 or T12PR24, respectively) in 194 Japanese patients infected with hepatitis C virus genotype 1b (HCV-1b). The study also evaluated whether ultradeep sequencing technology can predict at baseline the emergence of resistant variants after the start of therapy. Analysis of the data of the entire group indicated that an SVR was achieved in 78% of the patients. Multivariate analysis identified IL28B rs8099917 (genotype TT), the substitution of amino acid (aa) 70 (Arg70), response to prior treatment (naive or relapse), PEG-IFN dose (≥1.3 μg/kg of body weight), and treatment regimen (T12PR24) as significant determinants of SVR. Among patients of the T12PR24 group, 92% with genotype TT achieved an SVR, irrespective of a substitution at aa 70. In patients with the non-TT genotype, an SVR was achieved in 76% of those with Arg70, while only 14% of patients with the non-TT genotype, Gln70(His70), and nonresponse to ribavirin combination therapy achieved an SVR. Ultradeep sequencing was conducted for 17 patients who did not achieve an SVR to determine the emergence of resistant variants during therapy. De novo resistant variants were detected in 16 of 17 patients (94%), regardless of the variant frequencies detected at baseline. In conclusion, the results indicate that the response to triple therapy can be predicted by the combination of host, viral, and treatment factors and that it is difficult to predict at baseline the telaprevir-resistant variants that emerge during triple therapy, even with the use of ultradeep sequencing. 相似文献
9.
10.
Effects of alcohol consumption on multiple hepatocarcinogenesis in patients with fatty liver disease
Yorinari Ochiai M.D. Ph.D Yusuke Kawamura Masahiro Kobayashi Junichi Shindoh Yuta Kobayashi Satoshi Okubo Nozomu Muraishi Akira Kajiwara Soichi Iritani Shunichiro Fujiyama Tetsuya Hosaka Satoshi Saitoh Hitomi Sezaki Norio Akuta Fumitaka Suzuki Yoshiyuki Suzuki Kenji Ikeda Yasuji Arase Masaji Hashimoto Hiromitsu Kumada 《Hepatology research》2021,51(1):62-68